Vagal nerve stimulation (VNS) is a method used for delivering electrical impulses to the vagus nerve. The vagus nerve acts as a translator between the gut and the brain. The method involves the implantation of a device under the clavicle with lead wires being wrapped around the vagus nerve for sending out electrical impulses. The global vagal nerve stimulation market report by Market Research Future (MRFR) compiled by reputed analysts enumerates drivers, challenges, and opportunities in a comprehensive manner.
Vagal Nerve Stimulation (VNS) Market Overview
The global vagal nerve stimulation market size is expected to balloon at 8.68% CAGR during the forecast period (2017-2023). Rise in number of neurological disorders such as epilepsy, depression, migraine, and others is one of the biggest drivers of the market. According to the World Health Organization (WHO), neurological disorders accounted for 4.5-11% of all diseases in low-income and mid-income economies. High need for better treatment techniques and influx of capital into research and development by pharmaceutical and biotechnology firms can create opportunity of growth for the market.
Development of novel technologies for epilepsy treatment and favorable reimbursement policies proposed by governments in alliance with health coverage companies can persuade patients for the treatment. Research for the management and treatment of muscle function and organ disorders is likely to widen the scope of VNS manufacturers in the market.
Paucity of skilled surgeons and high costs of neurostimulation devices can pose a challenge to the market growth. Side-effects of cardiac arrest and probability of triggering a stroke can lead to hesitancy among doctors for prescribing the treatment.
Vagal Nerve Stimulation (VNS) Market Segmentation
The global vagal nerve stimulation market is segmented by product, application, and end-user.
By product, it is segmented into external VNS devices and implantable VNS devices.
By application, it is segmented into migraine, epilepsy, depression, and others.
By end-user, it is segmented into ambulatory surgical centers, hospitals, and others.
Vagal Nerve Stimulation (VNS) Market Regional Analysis
Asia Pacific (APAC), the Americas, Europe, and the Middle East & Africa (MEA) are major regions discussed in the global vagal nerve stimulation market.
The Americas accounted for 43% market share in 2016. Rising government support for research and development into neurological disorders, high healthcare spending, and sophisticated healthcare infrastructure and framework for major manufacturers to enter the region can bode well for the market growth. Presence of large players as well as their increased capacity to invest in sufficient amount of capital can encourage the market proliferation during the forecast period.
Europe holds the second position in the market standings due to availability of sufficient funds for research and development and rise in government support. On the other hand, the APAC region has latent potential for growth due to economies of China, South Korea, Japan, and India. The increased healthcare budget of economies, large patient pool, and development of neurostimulation technology are factors which can boost the regional market growth.
Lastly, the MEA region can offer limited returns growth and revenue-wise due to insufficient funding by governments and a paucity of healthcare infrastructure.
Obtain Premium Research Report Details @ https://www.marketresearchfuture.com/reports/vagal-nerve-stimulation-market-4479
Vagal Nerve Stimulation (VNS) Market Competition Outlook
LivaNova PLC, ElectroCore Medical LLC, EnteroMedics Inc., NeuroMetrix, Inc., Boston Scientific Corporation, Inspire Medical Systems, Inc., Cyberonics, Inc., ImThera Medical, and others are prominent names currently operational in the global vagal nerve stimulation market. Collaborations between medical device manufacturers and hospitals for measuring the efficacy of devices is likely to result in faster development of effective devices. For instance, the Massachusetts General Hospital decided to collaborate with electroCore, Inc., for attaining sufficient clinical trial data for gauging the performance of VNS Therapy for treatment of depression, migraine, and other neurological disorders.
Recently, LivaNova PLC was celebrating the success of its proprietary VNS Therapy System by proving to be effective for the treatment of drug-resistant epilepsy (DRE).
